Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).
Bioxodes with management changes
AppointmentsBioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).
Enhanc3D Genomics raises £10m in Series A financing
Latest NewsCambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors.
Univercells SA raises €44m in first close of its Series D
Latest NewsBelgian CDMO Univercells SA has raised €44m through the first close of its Series D financing round led by Belgian and international investors. I
PULSE: At the heart of Switzerland’s health valley
Sponsored PublicationsMost people know Switzerland for its watches, mountains, and chocolate. But biopharma professionals know that this country in the heart of Europe offers much more: the ideal setting for innovation and production in the fields of pharma and biotech.
Adrenomed set to start pivotal trial in sepsis
Latest NewsGerman Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study.
A spotlight on tomorrow’s CRO
BackgroundThe CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?
Mablink raises $31m in Series A financing
Latest NewsExperts showcase next-gen biotech solutions to climate crisis
Latest NewsIndustry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector.
Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
Latest NewsPrecision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia.
Knowledge-based contract services
BackgroundTo install a newly created Chief Scientific Officer position and to hire a biotech veteran is a signal sent by Rentschler Biopharma, celebrating 150 years.